Quantum BioPharma Announces Private Placement to Strengthen Financial Position and Voting Structure

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, generating gross proceeds of up to $750. The offering, which received shareholder approval on September 26, 2025, is expected to be fully subscribed by entities controlled by company insiders Zeeshan Saeed and Anthony Durkacz. This strategic financing move represents a significant development for the biopharmaceutical company's capital structure and governance framework.

The completion of this private placement will substantially alter the company's voting dynamics, with voting rights attached to the Class A shares increasing to 75.27%. This restoration brings the voting power nearly back to its original level when Quantum BioPharma went public in 2018, representing a meaningful shift in corporate control. The company has indicated that the proceeds from this offering will be allocated toward general working capital requirements, supporting ongoing operations and development initiatives.

Quantum BioPharma maintains a diverse portfolio of therapeutic candidates targeting challenging medical conditions. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has demonstrated potential in preclinical models for preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. The company's research focus extends across neurodegenerative disorders, metabolic conditions, and alcohol misuse disorders, positioning it in several high-need therapeutic areas.

The company's business strategy includes maintaining strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additionally, Quantum BioPharma retains significant rights and financial interests in unbuzzd(TM), having spun out the OTC version to Unbuzzd Wellness Inc. while maintaining 20.11% ownership as of March 31, 2025. The agreement includes royalty payments of 7% of sales until payments total $250 million, after which the royalty decreases to 3% in perpetuity, while Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical applications. Investors can access additional company information through the corporate newsroom available at https://ibn.fm/QNTM.